Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.72 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601094 | 0.89 | LMNA (0.66) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL26601242 | 0.85 | MEN1 (0.72) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL26601008 | 0.84 | LMNA (1.00) | LMNATP53THRBPOLBMAPT | |
| SCHEMBL30670747 | 0.82 | LMNA (0.58) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL26601211 | 0.82 | LMNA (0.58) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL26601040 | 0.82 | LMNA (0.76) | LMNATP53THRBPOLBMAPT | |
| SCHEMBL26601012 | 0.82 | LMNA (0.68) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL26600962 | 0.82 | TP53 (0.60) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL30670760 | 0.81 | TP53 (0.62) | LMNATP53MEN1KMT2ATHRB | |
| SCHEMBL26601240 | 0.81 | TP53 (0.62) | LMNATP53MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | disclosed |
| EP-4511112-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | TFEB, MITF, CREBBP | LMNA 852/4885TP53 1013/4885MEN1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.